Johnson & Johnson (JNJ)
275.23
-3.20 (1.15%)
Upcoming Events
Latest Headlines
Form 4 JOHNSON & JOHNSON For: Sep 02 Filed by: Schmid Timothy
September 4, 2026 9:08 AM - SEC Filing
Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
September 2, 2026 4:21 PM - BizWire
Form 144 JOHNSON & JOHNSON Filed by: Schmid Timothy
September 2, 2026 11:27 AM - SEC Filing
Form 3 JOHNSON & JOHNSON For: Sep 01 Filed by: Cavanaugh Thomas
September 1, 2026 4:53 PM - SEC Filing
Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
August 31, 2026 5:08 PM - BizWire
FDA: issues early alert on Abiomed heart pump controller purge cassette issue
August 26, 2026 2:00 PM - StreetInsider
FDA approves Johnson & Johnson drug for rare blood disorder
August 24, 2026 7:13 PM - StreetInsider
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
August 24, 2026 7:12 PM - PR NewsWire
Form 4 JOHNSON & JOHNSON For: Aug 17 Filed by: Taubert Jennifer L
August 18, 2026 6:31 PM - SEC Filing
Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
August 18, 2026 7:40 AM - StreetInsider
Form 144 JOHNSON & JOHNSON Filed by: Taubert Jennifer L
August 17, 2026 12:51 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Aug 13 Filed by: Duato Joaquin
August 14, 2026 4:40 PM - SEC Filing
Form 144 JOHNSON & JOHNSON Filed by: Duato Joaquin
August 13, 2026 2:12 PM - SEC Filing
Intuitive Surgical: Oppenheimer now bullish, sees competition being "crowded out"
August 12, 2026 8:32 AM - StreetInsider
Form N-PX JOHNSON & JOHNSON For: Jun 30
August 11, 2026 6:01 AM - SEC Filing
Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
August 10, 2026 4:27 PM - BizWire
Form 4 JOHNSON & JOHNSON For: Aug 05 Filed by: Duato Joaquin
August 7, 2026 5:51 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Aug 06 Filed by: Forminard Elizabeth
August 7, 2026 5:45 PM - SEC Filing
Morgan Stanley tracks US drug market prescriptions for week ending July 31
August 7, 2026 12:04 PM - StreetInsider
Form 144 JOHNSON & JOHNSON Filed by: Forminard Elizabeth
August 6, 2026 2:02 PM - SEC Filing
Form 13F-HR JOHNSON & JOHNSON For: Jun 30
August 6, 2026 10:46 AM - SEC Filing
Johnson & Johnson (JNJ) PT Raised to $287 at Guggenheim
August 6, 2026 6:44 AM - StreetInsider
Form 144 JOHNSON & JOHNSON Filed by: Duato Joaquin
August 5, 2026 6:08 PM - SEC Filing
Helus Pharma names ex-Intra-Cellular president as CEO
August 5, 2026 10:26 AM - StreetInsider
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
August 5, 2026 10:25 AM - Globe NewsWire
Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference
August 4, 2026 4:05 PM - BizWire
Every Few Decades, Aesthetics Gets a New Category. One Preclinical Company Thinks Its Extra Cellular Matrix Platform Could Create the Next One
August 4, 2026 9:05 AM - StreetInsider
Form 8-K JOHNSON & JOHNSON For: Aug 04
August 4, 2026 8:49 AM - SEC Filing
Johnson & Johnson names Tom Cavanaugh to lead Innovative Medicine unit
August 4, 2026 8:45 AM - StreetInsider
Johnson & Johnson’s Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September
August 4, 2026 8:45 AM - BizWire
Johnson & Johnson (JNJ) PT Raised to $280 at Raymond James
August 3, 2026 2:37 PM - StreetInsider
Microsoft joins, Broadcom exits Goldman's top-stocks list
August 3, 2026 8:01 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $282 at Wells Fargo
August 3, 2026 6:58 AM - StreetInsider
Goldman Monthly Update to US Director's Cut List
August 3, 2026 5:42 AM - StreetInsider
FDA grants priority review to J&J cancer drug for head and neck tumors
July 30, 2026 8:30 AM - StreetInsider
Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advance
July 30, 2026 8:30 AM - PR NewsWire
Johnson & Johnson buys Firefly Bio for $1B to expand oncology work
July 29, 2026 5:42 PM - StreetInsider
Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation
July 29, 2026 5:42 PM - BizWire
Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset
July 29, 2026 5:28 PM - BizWire
Form 8-K JOHNSON & JOHNSON For: Jul 29
July 29, 2026 5:25 PM - SEC Filing
Covista adds two directors with healthcare and tech backgrounds
July 28, 2026 8:00 AM - StreetInsider
Covista Names Emily C. Chiu and Leslie Storms to its Board of Directors
July 28, 2026 8:00 AM - BizWire
Johnson & Johnson (JNJ) call put ratio 1 call to 1 put unto J&J to settle ovarian talc claims
July 28, 2026 6:04 AM - StreetInsider
Form 8-K JOHNSON & JOHNSON For: Jul 27
July 28, 2026 6:03 AM - SEC Filing
Johnson & Johnson agrees to $5.5B settlement of ovarian talc claims
July 28, 2026 3:08 AM - StreetInsider
Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation
July 27, 2026 6:31 PM - BizWire
Form 10-Q JOHNSON & JOHNSON For: Jun 28
July 23, 2026 4:05 PM - SEC Filing
J&J myeloma drug combo cuts disease progression risk by 89% in trial
July 23, 2026 8:31 AM - StreetInsider
TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
July 23, 2026 8:30 AM - PR NewsWire
FDA clears Johnson & Johnson's Ottava robotic surgical system
July 22, 2026 7:01 AM - StreetInsider
Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System
July 22, 2026 7:00 AM - BizWire
Form 4 JOHNSON & JOHNSON For: Jul 20 Filed by: Broadhurst Vanessa
July 21, 2026 5:28 PM - SEC Filing
Form 144 JOHNSON & JOHNSON Filed by: Broadhurst Vanessa
July 20, 2026 1:35 PM - SEC Filing
Johnson & Johnson (JNJ) PT Raised to $276 at Leerink
July 17, 2026 8:36 AM - StreetInsider
Freedom Capital Upgrades Johnson & Johnson (JNJ) to Buy
July 16, 2026 1:27 PM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $270 at JPMorgan
July 16, 2026 8:49 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $261 at Bernstein SocGen
July 16, 2026 8:46 AM - StreetInsider
Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award
July 16, 2026 8:11 AM - BizWire
DePuy Synthes acquires expandable spine implant maker
July 16, 2026 8:00 AM - StreetInsider
DePuy Synthes Acquires Expanding Innovations™
July 16, 2026 8:00 AM - BizWire
Johnson & Johnson (JNJ) PT Raised to $294 at Morgan Stanley
July 16, 2026 7:51 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $305 at Scotiabank
July 16, 2026 7:13 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $272 at Wells Fargo
July 16, 2026 6:56 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Johnson & Johnson (JNJ)
July 16, 2026 6:40 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $260 at Stifel
July 15, 2026 3:35 PM - StreetInsider
Form 8-K JOHNSON & JOHNSON For: Jul 15
July 15, 2026 7:49 AM - SEC Filing
Johnson & Johnson beats estimates but shares dip
July 15, 2026 6:56 AM - StreetInsider
Johnson & Johnson (JNJ) Declares $1.34 Quarterly Dividend; 2.1% Yield
July 15, 2026 6:25 AM - StreetInsider
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026
July 15, 2026 6:25 AM - BizWire
Johnson & Johnson (JNJ) Tops Q2 EPS by 4c; raises guidance
July 15, 2026 6:21 AM - StreetInsider
Johnson & Johnson reports Q2 2026 results, raises 2026 outlook
July 15, 2026 6:20 AM - BizWire
Johnson & Johnson Q2 earnings preview: analysts eye product launch progress
July 15, 2026 3:00 AM - StreetInsider
Johnson & Johnson (JNJ) call put ratio 1.6 calls to 1 put into quarter results
July 14, 2026 11:28 AM - StreetInsider
Johnson & Johnson (JNJ) call put ratio 1.5 calls to 1 put into quarter results
July 14, 2026 6:41 AM - StreetInsider
Johnson & Johnson (JNJ) call put ratio 2.8 calls to 1 put into quarter results
July 13, 2026 11:09 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $300 at TD Cowen
July 13, 2026 8:49 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $287 at RBC Capital
July 13, 2026 7:13 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $284 at Morgan Stanley
July 8, 2026 8:08 AM - StreetInsider
FDA clears Johnson & Johnson dual-energy cardiac ablation catheter
July 8, 2026 7:45 AM - StreetInsider
Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
July 8, 2026 7:45 AM - BizWire
Increasing unusual put volume: AEVA SOLS LI TAP MTUM VSAT CMPS FPS CBRL JNJ NTAP
July 7, 2026 10:31 AM - StreetInsider
Johnson & Johnson (JNJ) PT Raised to $290 at HSBC
July 6, 2026 1:35 AM - StreetInsider
Increasing unusual put volume: XLI EQT ARKG ROST WEN KOS BKLN UUP DB DJ JNJ LOW FVRR
July 2, 2026 10:29 AM - StreetInsider
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
June 30, 2026 9:00 AM - StreetInsider
DePuy Synthes names Christina Zamarro as CFO, effective July 2026
June 29, 2026 4:33 PM - StreetInsider
J&J presents new IMAAVY data for myasthenia gravis at EAN 2026
June 26, 2026 12:35 PM - StreetInsider
Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis
June 26, 2026 12:35 PM - PR NewsWire
Johnson & Johnson (JNJ) PT Raised to $270 at Guggenheim
June 26, 2026 7:38 AM - StreetInsider
Form 11-K JOHNSON & JOHNSON For: Dec 31
June 25, 2026 5:16 PM - SEC Filing
Form 11-K JOHNSON & JOHNSON For: Dec 31
June 25, 2026 5:13 PM - SEC Filing
Johnson & Johnson to stay out of obesity drugs, focus on cancer, CEO says
June 17, 2026 11:15 AM - StreetInsider
Johnson & Johnson invests $1 billion in Jacksonville vision manufacturing
June 15, 2026 6:01 AM - StreetInsider
Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida
June 15, 2026 6:00 AM - BizWire
Johnson & Johnson shows positive results for TALVEY-DARZALEX drug combination
June 14, 2026 2:01 PM - StreetInsider
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple my
June 13, 2026 6:34 AM - PR NewsWire
Form 4 JOHNSON & JOHNSON For: Jun 11 Filed by: Wengel Kathryn E
June 12, 2026 5:24 PM - SEC Filing
Leerink highlights drug demand rebound after Memorial Day
June 12, 2026 2:42 PM - StreetInsider
Form 4 JOHNSON & JOHNSON For: Jun 09 Filed by: Woods Eugene A.
June 11, 2026 4:57 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Jun 09 Filed by: Pinto Daniel E
June 11, 2026 4:44 PM - SEC Filing
Form 4 JOHNSON & JOHNSON For: Jun 09 Filed by: HEWSON MARILLYN A
June 11, 2026 4:36 PM - SEC Filing
Form 144 JOHNSON & JOHNSON Filed by: Wengel Kathryn E
June 11, 2026 1:44 PM - SEC Filing
Johnson & Johnson expands US availability of TECNIS PureSee IOL
June 11, 2026 7:45 AM - StreetInsider
Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
June 11, 2026 7:45 AM - BizWire
Johnson & Johnson reports positive results for rare blood disorder treatment
June 11, 2026 7:43 AM - StreetInsider
Johnson & Johnson drug shows positive results for rare blood condition
June 11, 2026 2:03 AM - StreetInsider
IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease wi
June 11, 2026 2:03 AM - PR NewsWire
Johnson & Johnson faces $32 million verdict in Los Angeles asbestos case
June 10, 2026 11:22 AM - StreetInsider
Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
June 10, 2026 11:22 AM - BizWire
Johnson & Johnson to acquire Firefly Bio for $1 billion in cash
June 8, 2026 8:00 AM - StreetInsider
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
June 8, 2026 8:00 AM - BizWire
Full Article List
